Name: Ipamorelin 10mg (Research Peptide)
Brand: Verum Peptides
Price: 69 USD
Availability: InStock

Identification

Chemical name	Synthetic pentapeptide amide incorporating three non-coded residues
Common designation	Ipamorelin
Sequence	Aib-His-D-2-Nal-D-Phe-Lys-NH2
Length	5 residues, C-terminal amide
Non-standard residues	2-aminoisobutyric acid; D-2-naphthylalanine; D-phenylalanine
Molecular formula	C38H49N9O5
Molecular weight	711.9 g/mol, free base
CAS number	170851-70-4
Molecular target	Growth hormone secretagogue receptor (GHS-R1a), the receptor ghrelin acts on
Not a GHRH analogue	Binds a different receptor from sermorelin, tesamorelin and CJC-1295. See section 04.
Oxidation-sensitive residues	None. The sequence contains no methionine, cysteine, tryptophan or tyrosine.
Physical form	White lyophilized powder
Quantity supplied	10 mg nominal per unit
Country of manufacture	United States

Certificate of analysis - current lot

The interactive verification record is shown below, followed by the same information reproduced as text on this page and the full certificate as a document. The record does not depend on the embed loading.

Certificate of analysis - lot VNA7TB

Lot record

VNA7TB

Testing laboratory	Freedom Diagnostics, United States
Laboratory relationship	Independent third party. Not owned by, affiliated with, or operated by Verum.
Sample received	11 May 2026
Results reported	12 May 2026
Accession reference	2605110191
Analytical method	High-performance liquid chromatography with ultraviolet detection coupled to mass spectrometry (HPLC-UV / LC-MS)

Results, this lot

Identity, LC-MS	Confirmed as ipamorelin
Purity, HPLC-UV	99.90 %
Net peptide content	13.12 mg per unit
Appearance	White lyophilized powder
Mass confirmation	Three species assigned: [M+H]+ at m/z 713.2, [M+2H]2+ at 356.8 and the sodium adduct [M+Na]+ at 734.2

Purity and content figures above are specific to lot VNA7TB and are not a specification carried across other lots. Each lot is tested individually and reports its own results. A certificate that assigns the sodium adduct rather than leaving it as an unexplained peak is one where the spectrum has been interpreted rather than glanced at.

Testing scope

Panels differ between products and between lots. What follows is the scope of testing performed on this lot. Nothing is claimed unless it appears on the certificate for the lot supplied.

Performed

✓	Identity by LC-MS
✓	Purity by HPLC-UV
✓	Net peptide content
✓	Appearance by visual inspection
✓	Mass confirmation, three species assigned

Not performed

-	Stereochemical verification of the D-amino acids
-	Bacterial endotoxin
-	Sterility
-	Microbial enumeration
-	Elemental impurities
-	Residual solvents

The first entry in the right-hand column is the limitation worth naming on this molecule. Three of the five residues are non-standard, including two D-amino acids, and mass spectrometry cannot distinguish a D-amino acid from its L counterpart because they weigh the same. A substitution of that kind yields identical mass, similar chromatographic behaviour and a different receptor profile. Confirming stereochemistry requires chiral analysis, which is not part of this panel or of any standard peptide panel. Where a parameter is material to intended laboratory work, purchasers should verify it independently.

It is not in the class it is usually filed under

Ipamorelin is routinely shelved alongside sermorelin, tesamorelin and CJC-1295, each of which binds the growth hormone-releasing hormone receptor. Ipamorelin does not. It binds the growth hormone secretagogue receptor, a separate protein with a separate endogenous ligand. The two pathways converge on the same downstream output and are otherwise unrelated.

The compound also came out of a programme searching for members of its class with less collateral endocrine activity than their predecessors, and the published characterisation reports minimal effect on cortisol and prolactin relative to those earlier compounds. That selectivity profile rather than potency is what makes the molecule useful as a research tool, and it is the property most worth verifying rather than assuming in an assay design.

Single unit or blend

This compound is also supplied co-lyophilized with a GHRH analogue. A blend fixes the proportion of two compounds in one powder, which makes it impossible to vary one input while holding the other constant, impossible to run a single-component control, and impossible to attribute an observation to either pathway. Separate units answer questions a combined unit cannot. Work comparing the GHRH and secretagogue routes, or establishing a concentration-response relationship for either, requires this format.

Storage and laboratory handling

Lyophilized powder, transit	Stable at ambient temperature during shipping and short-term handling. Cold-chain transport is not required.
Lyophilized powder, storage	−20 °C, protected from light, container tightly closed
Solubility	Sterile laboratory-grade water or a defined aqueous buffer appropriate to the assay
Solution, storage	2 °C to 8 °C, protected from light. Materially less stable than the dry powder.
Freeze-thaw	Avoid repeated cycles. Aliquot at first preparation where the protocol allows.
Sequence-specific note	The D-amino acids and the C-terminal amide make this pentapeptide unusually resistant to enzymatic degradation, and the sequence carries no oxidation-sensitive residues. Both are real advantages and both are frequently overread. Resistance to peptidases and to oxidation is not stability in aqueous storage; this peptide hydrolyses in solution like any other.
Personal protection	Handle under standard laboratory conditions with gloves, eye protection and a laboratory coat.

Preparation conditions are the responsibility of the receiving laboratory. Verum provides no protocol, no preparation instruction, and no guidance on use.

Published literature

Rather than assemble a bibliography, this page points at one document. The FDA's briefing package prepared for the advisory committee review of ipamorelin is a systematic survey of the available evidence, written by reviewers with no commercial interest in the outcome, and it reaches a conclusion unfavourable to anyone selling this compound. That makes it more useful than a curated reading list and considerably harder to accuse of selection bias.

FDA advisory committee briefing document, ipamorelin, PDF →

Regulatory status

United States	Not approved by the FDA for any indication. Not on the section 503A bulk drug substances list, and it cannot lawfully be compounded for a patient.
Category 2 history	Placed on Category 2 of the interim 503A list in September 2023, the designation for substances the agency considers to present significant safety risks. Removed in September 2024 after the parties who nominated it withdrew their nominations. A great deal of marketing copy stops the account there.
Advisory committee	The Pharmacy Compounding Advisory Committee took the substance up on 29 October 2024, with the agency's own analysis recommending against inclusion, and voted against adding it to the 503A list. The reasons on the record were insufficient human safety data, mechanistic concerns about unintended endocrine effects, and efficacy data confined to small or open-label studies.
In context	Several other substances received favourable committee recommendations in July 2026, and some compounds acting on the GHRH pathway have a lawful prescription route through a compounding pharmacy. This one has neither. It was reviewed, and the answer was no.
Other jurisdictions	No marketing authorisation is held anywhere.
Athletic competition	Prohibited under World Anti-Doping Agency rules.
Status date	Accurate as of August 2026. Verify the current position independently.

Read the briefing document linked above rather than take anyone's characterisation of it, including this one.

Purchase eligibility

By placing an order you confirm each of the following:

✓	You are at least 21 years of age.
✓	You are a qualified researcher, or are purchasing on behalf of a research institution or commercial laboratory.
✓	The material will be used solely for in vitro laboratory research.
✓	The material will not be administered to humans or to animals, and will not be resold or transferred for any such purpose.
✓	You are responsible for compliance with all federal, state and local law governing receipt, handling, storage and use.

Confirmation is recorded at checkout against your order. Verum reserves the right to decline or cancel any order.

Supply

Orders placed before the daily cutoff are dispatched the same day from our United States warehouse. Domestic orders typically arrive within two business days. A tracking reference is issued by email once the consignment leaves the facility. Each unit carries a scannable code linking to the certificate for its own lot.

Not for human or veterinary use. Not for use in diagnostic or therapeutic procedures. This product is a laboratory reagent. Nothing on this page constitutes medical advice, a recommendation for personal use, or a representation that this material is safe or effective for any purpose. No statement here has been evaluated by the U.S. Food and Drug Administration.